Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Schorb

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Neuropathology and Applied Neurobiology|March 7, 2023
Patient-derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphomaLisa Kristina Isbell, Cordula Tschuch, Soroush Doostkam, et al.
Neuro-Oncology|September 15, 2023
Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomasEliza M Lauer, Ella Riegler, Jurik A Mutter, et al.
Cancers|January 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European RegistryBertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Cancers|March 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124Bertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
BMC Cancer|August 18, 2023
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trialLisa K Isbell, Roswitha Uibeleisen, Alexander Friedl, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.
Haematologica|October 27, 2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphomaJahanzaib Khwaja, Amy A Kirkwood, Lisa K Isbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2022
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain LymphomasJurik A Mutter, Stefan K Alig, Mohammad S Esfahani, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Neuropathology and Applied Neurobiology|March 7, 2023
Patient-derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphomaLisa Kristina Isbell, Cordula Tschuch, Soroush Doostkam, et al.
Neuro-Oncology|September 15, 2023
Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomasEliza M Lauer, Ella Riegler, Jurik A Mutter, et al.
Cancers|January 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European RegistryBertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Cancers|March 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124Bertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
BMC Cancer|August 18, 2023
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trialLisa K Isbell, Roswitha Uibeleisen, Alexander Friedl, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.
Haematologica|October 27, 2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphomaJahanzaib Khwaja, Amy A Kirkwood, Lisa K Isbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2022
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain LymphomasJurik A Mutter, Stefan K Alig, Mohammad S Esfahani, et al.
Pageof 5